TruSight Software Suite—Supporting Variant Analysis in Rare Disease

January 13, 2020

Next-generation sequencing (NGS) is becoming commonplace when seeking a diagnosis for rare genetic disease. This can create a bottleneck when analyzing and interpreting the billions of base pairs and millions of variants in the genome. Introducing a new suite of software tools to streamline this important analysis. Designed to provide comprehensive information seamlessly at your fingertips—the TruSight™ Software Suite enables informed analysis and empowered interpretation. Subscribe to the Illumina video channel A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos View Illumina webinars View Illumina product videos View Illumina support videos

Share this article on